NCT00542425

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 222 (actual)
• Sponsor: Radius Health, Inc. · Industry
• Sex: Female
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.

Detailed description

This is a randomized, parallel-group, multi-center, dose-finding study to evaluate the effects of BA058 in the treatment of otherwise healthy postmenopausal women with osteoporosis.

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	teriparatide	teriparatide 20 µg subcutaneous daily
DRUG	Placebo	Placebo subcutaneous daily
DRUG	BA058 20 µg	BA058 20 µg subcutaneous daily
DRUG	BA058 40 µg	BA058 40 µg subcutaneous daily
DRUG	BA058 80 µg	BA058 80 µg subcutaneous daily

Timeline

• Start date: 2007-04-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2007-10-11
• Last updated: 2017-10-30
• Results posted: 2010-07-29

Locations

1 site across 1 country: United States